TRENTON, N.J. (AP) — Drugmaker Pfizer Inc. said Monday that a late-stage patient study found an extended-release version of its pain drug Lyrica relieved pain better than a dummy pill in some patients, but the improvement didn’t last much longer.
The study, funded by the New York-based drugmaker, is one of three late-stage patient tests aimed at gaining approval of Lyrica for another use, as a long-term daily pill to limit pain from fibromyalgia. That’s a chronic condition, affecting more than 5 million Americans, involving bouts of widespread pain and tenderness.
Stay informed.Stay ahead.
Join Washington Examiner for unlimited access to the news, analysis, and commentary that matter most.
See Options
Already a member? Log in
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.
